Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
acetate, acitretin, acquiree, adalimumab, adultsRegnite, affinity, alemtuzumab, allHorizant, anthrolin, antibody, ascending, aspect, assert, assigned, ATRA, attorney, Aubagio, Avonex, batch, Bayer, benchmark, Berkeley, Betaseron, broadened, broader, broadly, Budget, byHorizantor, category, chain, cladribine, cleavage, cohort, commercializeHorizantcould, commercializeHorizanton, commercializingHorizantand, compliant, compressed, concealing, contributory, Copaxone, creatinine, currentHorizant, customer, cyclosporine, Daclizumab, deducting, defraud, deliverHorizantto, developingHorizant, developmental, differentiated, differentiation, discussingHorizantwith, distributeHorizant, Doctor, elevated, Enbrel, encephalopathy, energy, entertainment, ester, etanercept, EU, experimental, Extavia, fact, falsifying, fashion, feedback, Fifty, fingolimod, foregone, forHorizantand, forHorizantback, forHorizantcurrently, forHorizantor, forHorizantto, formula, fraudulent, fromHorizantproduct, fromRegnite, frustrated, Fumaderm, GABAB, gave, Genentech, genetic, Gilenya, glatiramer, Gregory, heart, HIPAA, HITECH, Horizanttransition, Humira, hyperlipidemia, hypertension, ideation, idiopathic, indirect, inflammatory, infliximab, instance, intent, interchangeability, intervention, intolerability, intolerance, inventory, itching, jeopardy, Labour, landlord, Laquinimod, Larger, Lemtrada, Likewise, limb, liver, main, manageHorizant, manufactureHorizantor, message, methotrexate, mixed, MMA, mobility, morphology, Movecto, multifocal, mutual, myelin, natralizumab, neurodegeneration, neurodegenerative, neuroprotective, nitrogen, Obama, occasionally, ofHorizantduring, ofHorizantfollowing, ofHorizanton, ofRegniteor, onHorizantif, orHorizant, outweigh, perception, persuasive, PGIC, pharmacovigilance, photoaging, phototherapy, possession, Postemployment, predisposition, preempted, preexisting, premium, prescribeHorizant, privacy, progressive, progressively, promoteHorizant, protein, radiolabeled, Rebif, red, reducingHorizant, refilling, regardingHorizant, Remicade, remission, Rytary, scalable, scenario, scheme, Serono, shelf, SI, Sifrol, Sixty, standardized, Stelara, supplyHorizant, switch, Syntex, Taxpayer, teaching, Tecfidera, template, teratogenicity, teriflunomide, theory, thick, threshold, train, tranche, transmission, trillion, tumorigenic, Tysabri, ultraviolet, unavailability, underwriting, underwritten, unexpired, unfamiliarity, unproven, untested, untoward, urea, usability, usable, ustekinumab, Veterinary, violate, violated, violation, vitamin, warehousing, weighted
Removed:
achievability, acknowledgment, AMT, API, approximate, authorization, bioavailability, capture, ceased, choice, clearance, compare, concurrently, continual, culmination, debate, defer, depression, Device, died, diffusion, diminished, discharged, discontinued, divided, division, Duodopa, Eastman, evidenced, execution, exploit, factor, greatest, gunshot, HIV, Homeownership, identifying, incident, ingredient, Kentucky, Kodak, localization, lowest, Manchester, marketplace, metabolized, nameHorizant, numerical, passive, pre, preclude, predominantly, procurement, producing, promise, propofol, proton, rating, recall, recognizing, reformat, refund, refundable, regulate, residual, resolution, resubmitted, securing, seize, slightly, Solvay, somnolence, Sterling, subsidized, suggesting, tablet, theAmerican, volunteer, wound
Filing tables
Filing exhibits
Related press release
XNPT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statements (Form S-8 Nos. 333-125518, 333-133357, 333-142844, 333-150730, 333-159021, 333-166760, 333-171626, 333-178947 and 333-185940) pertaining to the 1999 Stock Plan, the 2005 Equity Incentive Plan, the 2005 Non-Employee Directors’ Stock Option Plan and the 2005 Employee Stock Purchase Plan of XenoPort, Inc., the New Hire Option Agreements between each of Vincent J. Angotti and David A. Stamler, M.D. and XenoPort, Inc., the New Hire Stock Unit Award Agreements between each of Vincent J. Angotti and David A. Stamler, M.D. and XenoPort, Inc. and the 2010 Inducement Award Plan, and |
| (2) | Registration Statement (Form S-3 No. 333-167972) of XenoPort, Inc. and in the related Prospectus; |
of our reports dated March 14, 2013, with respect to the financial statements of XenoPort, Inc. and the effectiveness of internal control over financial reporting of XenoPort, Inc. included in this Annual Report (Form 10-K) of XenoPort, Inc. for the year ended December 31, 2012.
/s/ Ernst & Young LLP
Redwood City, California
March 14, 2013